Archives of Pharmacal Research最新文献

The dynamic roles of macrophages extracellular traps (METs) in immune regulation. 巨噬细胞胞外陷阱（METs）在免疫调节中的动态作用。

IF 6.9 3区医学

Archives of Pharmacal Research Pub Date : 2025-04-05 DOI: 10.1007/s12272-025-01540-6

Yunjin Shin, Hanyoung Bae, Chaelin Lee, Inmoo Rhee

引用次数: 0

The inhibition of endothelial DLL4-NOTCH1 signaling by 2'-hydroxyflavanone enhances anti-PD-1 therapy in melanoma. 2'-hydroxyflavanone 对内皮 DLL4-NOTCH1 信号的抑制增强了黑色素瘤的抗 PD-1 治疗。

IF 6.9 3区医学

Archives of Pharmacal Research Pub Date : 2025-04-02 DOI: 10.1007/s12272-025-01539-z

Jihye You, Seunghwan Ha, Doyoung Kim, Hyoung-Geun Kim, Se Ha Kim, Ji-Hak Jeong, Changmin Oh, Nam-In Baek, Jong Hwa Jung, Jeong Ah Kim, You Mie Lee

{"title":"The inhibition of endothelial DLL4-NOTCH1 signaling by 2'-hydroxyflavanone enhances anti-PD-1 therapy in melanoma.","authors":"Jihye You, Seunghwan Ha, Doyoung Kim, Hyoung-Geun Kim, Se Ha Kim, Ji-Hak Jeong, Changmin Oh, Nam-In Baek, Jong Hwa Jung, Jeong Ah Kim, You Mie Lee","doi":"10.1007/s12272-025-01539-z","DOIUrl":"https://doi.org/10.1007/s12272-025-01539-z","url":null,"abstract":"<p><p>Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapeutics; however limited patient responses necessitate combination strategies to improve therapeutic efficacy. Among potential combination partners, drugs targeting DLL4-NOTCH1 signaling pathway-a critical regulator of vascular function-show promise as angiogenesis modulators, but their clinical development have been hindered by safety concerns. To address this challenge, we adopted a novel approach by screening natural compounds with a long history of human consumption. Building upon our earlier findings, we identified three inhibitors of DLL4-NOTCH1 signaling: steppogenin, sanggenon F, and dehydrovomifoliol. Steppogenin inhibited both DLL4 and NOTCH1 activities, while sanggenon F and dehydrovomifoliol selectively suppressed DLL4 and NOTCH1 activity, respectively. We assessed their impact on key angiogenic processes, including endothelial cell migration, sprouting, and proliferation, and elucidated the relative contributions of selective DLL4 or NOTCH1 inhibition to the anti-angiogenic effect. By comparing structurally similar compounds, we identified the 2'-hydroxyflavanone moiety as a key element for DLL4 inhibition. Notably, combining steppogenin with an ICI demonstrated that a nature-derived angiogenesis inhibitor can boost the anti-cancer effect of ICI in a mouse melanoma allograft model. This comprehensive analysis of structure-activity relationships and in vivo therapeutic evaluation provides valuable insights into the development of novel anti-angiogenic compounds for combination therapy with ICIs in cancer treatment.</p>","PeriodicalId":8287,"journal":{"name":"Archives of Pharmacal Research","volume":" ","pages":""},"PeriodicalIF":6.9,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143762934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Covalent organic frameworks in cancer theranostics: advancing biomarker detection and tumor-targeted therapy

IF 6.9 3区医学

Archives of Pharmacal Research Pub Date : 2025-03-22 DOI: 10.1007/s12272-025-01536-2

Sonia Iranpour, Amir Abrishami, Amir Sh. Saljooghi

{"title":"Covalent organic frameworks in cancer theranostics: advancing biomarker detection and tumor-targeted therapy","authors":"Sonia Iranpour, Amir Abrishami, Amir Sh. Saljooghi","doi":"10.1007/s12272-025-01536-2","DOIUrl":"10.1007/s12272-025-01536-2","url":null,"abstract":"<div><p>In recent years, covalent organic frameworks (COFs) have garnered considerable attention in the field of onco-nanotechnology as a new type of nanoporous construct due to their promising physicochemical properties, ease of modification, and ability to be coupled with several moieties and therapeutic molecules. They can not only be used as biocompatible nanocarriers to deliver therapeutic payloads to the tumor zone selectively but can also be combined with a variety of therapeutic modalities to achieve the desired treatments. This review comprehensively presented recent achievements and progress in COF-based cancer diagnosis, detection, and cancer therapy to provide a better prospect for further research. Herein our primary emphasis lies on exploring the application of COFs as potential sensors for cancer-derived biomarkers that have received comparatively less attention in previous discussions. While the utilization of COFs in solid tumor therapy has faced significant challenges in scientific research and clinical applications, we reviewed the most promising features that underscore their potential in cancer theranostics.</p></div>","PeriodicalId":8287,"journal":{"name":"Archives of Pharmacal Research","volume":"48 3","pages":"183 - 211"},"PeriodicalIF":6.9,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143676710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of binge drinking on alcoholic liver disease

IF 6.9 3区医学

Archives of Pharmacal Research Pub Date : 2025-03-04 DOI: 10.1007/s12272-025-01537-1

Jisoo Kang, Seol Hee Park, Mushira Khanam, Seo Bhin Park, Sumin Shin, Wonhyo Seo

{"title":"Impact of binge drinking on alcoholic liver disease","authors":"Jisoo Kang, Seol Hee Park, Mushira Khanam, Seo Bhin Park, Sumin Shin, Wonhyo Seo","doi":"10.1007/s12272-025-01537-1","DOIUrl":"10.1007/s12272-025-01537-1","url":null,"abstract":"<div><p>Numerous studies have examined the pathophysiological changes induced by chronic alcohol (ethanol) consumption and the underlying mechanisms, while much less attention has been devoted to understanding the health impacts of binge drinking. Binge drinking is defined as the excessive consumption of alcohol within a single drinking episode, and is the typical consumption pattern among young people in Western countries. While most young binge drinkers are not clinically alcohol dependent, binge drinking has emerged as a significant social and public health concern. The circulating alcohol consumed during binge episodes permeates cellular membranes throughout the body, exerting profound effects on multiple organs, and signaling pathways. Regular binge drinking eventually induces hepatic steatosis (fatty liver), initiates acute inflammation, and accelerates neutrophil infiltration, de novo lipogenesis, adipocyte death/lipolysis, and the production of nonoxidative alcohol metabolites, processes that synergize to damage liver tissue and impair liver function. Metabolic abnormalities such as diabetes and obesity can also exacerbate the progression of alcohol-related liver disease among binge drinkers. Several animal models have been developed to evaluate the pathophysiological changes resulting from binge drinking; however, the pathogenesis of binge drinking is not fully understood due to differences in alcohol metabolism between animal models and humans. Thus, given the high prevalence and severe health implications of binge drinking, there is an urgent need for comprehensive experimental and clinical investigations to unravel the associated pathophysiological changes. This review summarizes recent research findings on the impact of binge drinking, specifically focusing on its contributions to alcoholic liver injury.</p></div>","PeriodicalId":8287,"journal":{"name":"Archives of Pharmacal Research","volume":"48 3","pages":"212 - 223"},"PeriodicalIF":6.9,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143539840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A novel 11β-HSD1 inhibitor ameliorates liver fibrosis by inhibiting the notch signaling pathway and increasing NK cell population

IF 6.9 3区医学

Archives of Pharmacal Research Pub Date : 2025-02-15 DOI: 10.1007/s12272-025-01534-4

Ji Eun Kim, Yun Kim, Jiwon Bae, Eileen Laurel Yoon, Hyun Sung Kim, Sung Ryol Lee, Tae Hyun Yoon, Dae Won Jun

{"title":"A novel 11β-HSD1 inhibitor ameliorates liver fibrosis by inhibiting the notch signaling pathway and increasing NK cell population","authors":"Ji Eun Kim, Yun Kim, Jiwon Bae, Eileen Laurel Yoon, Hyun Sung Kim, Sung Ryol Lee, Tae Hyun Yoon, Dae Won Jun","doi":"10.1007/s12272-025-01534-4","DOIUrl":"10.1007/s12272-025-01534-4","url":null,"abstract":"<div><p>11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) regulates hepatic glucose output and is implicated in liver fibrosis. We aimed to investigate the anti-fibrotic effect of a novel 11β-HSD1 inhibitor in a thioacetamide (TAA)-induced liver fibrosis mouse model. Mice were administered TAA for 19 weeks and treated with 11β-HSD1 inhibitor for the last 9 weeks. Treatment with 11β-HSD1 inhibitor significantly reduced fibrosis area, alanine aminotransferase, and aspartate aminotransferase levels compared to the TAA-only group. Inhibition of 11β-HSD1 led to a decrease in intracellular cortisol levels, which suppressed the activation of hepatic stellate cells. RNA sequencing revealed significant downregulation of the Notch signaling pathway, including reduced expression of Notch ligands and receptors, as well as downstream genes. Furthermore, 11β-HSD1 inhibition enhanced NK cell-mediated immune responses, as indicated by the upregulation of NK cell-related genes and increased NK cell populations confirmed by mass cytometry. This increase in NK cell activity contributed to the clearance of activated HSCs and the attenuation of fibrosis. These findings suggest that 11β-HSD1 inhibition alleviates liver fibrosis through Notch pathway suppression and enhancement of NK cell-mediated immune responses. Our results support the therapeutic potential of a novel 11β-HSD1 inhibitor for treating liver fibrosis.</p></div>","PeriodicalId":8287,"journal":{"name":"Archives of Pharmacal Research","volume":"48 2","pages":"166 - 180"},"PeriodicalIF":6.9,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143424898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Retraction Note: Anti-inflammatory effect of atorvastatin on vascular reactivity and insulin resistance in fructose fed rats

IF 6.9 3区医学

Archives of Pharmacal Research Pub Date : 2025-02-12 DOI: 10.1007/s12272-025-01535-3

Mona F. Mahmoud, Mohamed El-Nagar, Hany M. El-Bassossy

引用次数: 0

Discovery of novel naphthalene-based diarylamides as pan-Raf kinase inhibitors with promising anti-melanoma activity: rational design, synthesis, in vitro and in silico screening

IF 6.9 3区医学

Archives of Pharmacal Research Pub Date : 2025-02-08 DOI: 10.1007/s12272-025-01533-5

Ahmed Elkamhawy, Usama M. Ammar, Minkyoung Kim, Anam Rana Gul, Tae Jung Park, Kyeong Lee

{"title":"Discovery of novel naphthalene-based diarylamides as pan-Raf kinase inhibitors with promising anti-melanoma activity: rational design, synthesis, in vitro and in silico screening","authors":"Ahmed Elkamhawy, Usama M. Ammar, Minkyoung Kim, Anam Rana Gul, Tae Jung Park, Kyeong Lee","doi":"10.1007/s12272-025-01533-5","DOIUrl":"10.1007/s12272-025-01533-5","url":null,"abstract":"<div><p>Raf kinase enzymes are often dysregulated in melanoma. While sorafenib demonstrates strong activity against wild-type B-Raf, it fails to effectively inhibit the mutated form of B-Raf. In this study, sorafenib served as a lead compound for the development of new derivatives designed to enhance inhibitory activity across multiple Raf isoforms (pan-Raf inhibitors). Novel naphthalene-based diarylamide derivatives were subsequently designed, synthesized, and evaluated for their biological activity against various Raf kinase isoforms and the melanoma A375 cell line. Among these, compound <b>9a</b>, containing a difluoromethoxy group, demonstrated strong inhibitory activity across B-Raf<sup>WT</sup>, B-Raf<sup>V600E</sup>, and c-Raf. Additionally, it induced G2/M phase arrest and triggered dose-dependent apoptosis, effectively suppressing both cell proliferation and survival. Compound <b>9a</b> also exhibited high selectivity for Raf isoforms with minimal off-target effects, underscoring its specificity and therapeutic potential for Raf-driven malignancies.</p></div>","PeriodicalId":8287,"journal":{"name":"Archives of Pharmacal Research","volume":"48 2","pages":"150 - 165"},"PeriodicalIF":6.9,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12272-025-01533-5.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143370348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tumor microenvironment regulation by reactive oxygen species-mediated inflammasome activation

IF 6.9 3区医学

Archives of Pharmacal Research Pub Date : 2025-01-31 DOI: 10.1007/s12272-025-01532-6

Jeong-Hoon Jang, Do-Hee Kim, Kyung-Soo Chun

{"title":"Tumor microenvironment regulation by reactive oxygen species-mediated inflammasome activation","authors":"Jeong-Hoon Jang, Do-Hee Kim, Kyung-Soo Chun","doi":"10.1007/s12272-025-01532-6","DOIUrl":"10.1007/s12272-025-01532-6","url":null,"abstract":"<div><p>Tumor microenvironment (TME) is composed of diverse cell types whose interactions, both direct and indirect, significantly influence tumorigenesis and therapeutic outcomes. Within TME, reactive oxygen species (ROS) are produced by various cells and exhibit a dual role: moderate ROS levels promote tumor initiation and progression, whereas excessive levels induce cancer cell death, influencing the efficacy of anticancer therapies. Inflammasomes, cytosolic multiprotein complexes, are pivotal in multiple stages of tumorigenesis and play a crucial role in establishing the inflammatory TME. By releasing cytokines such as IL-1β and IL-18, inflammasomes contribute to immune cell recruitment and sustain a chronic inflammatory state that supports tumor growth. ROS are critical regulators of inflammasome activation, with the impact of ROS-mediated activation differing across cell types, leading to distinct influences on tumor progression and therapeutic responses. This review explores how ROS drive inflammasome activation in various TME-associated cells and the reciprocal ROS generation induced by inflammasomes, examining their multifaceted impact on tumorigenesis and therapeutic efficacy. By elucidating the complex interplay between ROS and inflammasomes in TME, we provide insights into potential therapeutic approaches that could modulate cancer progression and enhance treatment outcomes.</p></div>","PeriodicalId":8287,"journal":{"name":"Archives of Pharmacal Research","volume":"48 2","pages":"115 - 131"},"PeriodicalIF":6.9,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143063445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Physiologically based pharmacokinetic (PBPK) modeling of gliclazide for different genotypes of CYP2C9 and CYP2C19 格列齐特对不同基因型CYP2C9和CYP2C19的生理药代动力学（PBPK）建模

IF 6.9 3区医学

Archives of Pharmacal Research Pub Date : 2025-01-06 DOI: 10.1007/s12272-024-01528-8

Hye-Jung Park, Sang-Ho Lee, Pureum Kang, Chang‑Keun Cho, Choon-Gon Jang, Seok-Yong Lee, Yun Jeong Lee, Jung‑Woo Bae, Chang-Ik Choi

{"title":"Physiologically based pharmacokinetic (PBPK) modeling of gliclazide for different genotypes of CYP2C9 and CYP2C19","authors":"Hye-Jung Park, Sang-Ho Lee, Pureum Kang, Chang‑Keun Cho, Choon-Gon Jang, Seok-Yong Lee, Yun Jeong Lee, Jung‑Woo Bae, Chang-Ik Choi","doi":"10.1007/s12272-024-01528-8","DOIUrl":"10.1007/s12272-024-01528-8","url":null,"abstract":"<div><p>Gliclazide is a sulfonylurea hypoglycemic agent used to treat type 2 diabetes. Cytochrome P450 (CYP) 2C9 and CYP2C19 are primarily involved in the hepatic metabolism of gliclazide. The two CYP isozymes are highly polymorphic, and their genetic polymorphisms are known to significantly impact the pharmacokinetics of gliclazide. In the present study, the physiologically based pharmacokinetic (PBPK) model was developed using data from subjects whose pharmacokinetic parameters were influenced by the genetic polymorphisms of the CYP metabolic enzymes. All predicted plasma concentration–time profiles generated by the model showed visual agreement with the observed data, and the pharmacokinetic results were within the twofold error range. Individual simulation results showed additional metrics: average fold error (− 0.19 to 0.07), geometric mean fold error (1.13–1.56), and mean relative deviation (1.18–1.58) for AUC, C<sub>max</sub>, T<sub>1/2</sub>, T<sub>max</sub>, CL/F, and V<sub>d</sub> values. These results met the standard evaluation criteria. The validation across a total of 8 studies and 7 races also satisfied the twofold error range for AUC, C<sub>max</sub>, and T<sub>1/2</sub>. Therefore, variations in gliclazide exposure according to individuals’ <i>CYP2C9</i> and <i>CYP2C19</i> genotypes were properly captured through PBPK modeling in this study. This PBPK model may allow us to predict the gliclazide pharmacokinetics of patients with genetic polymorphisms in <i>CYP2C9</i> and <i>CYPC19</i> under various conditions, ultimately contributing to the realization of individualized drug therapy.</p></div>","PeriodicalId":8287,"journal":{"name":"Archives of Pharmacal Research","volume":"48 3","pages":"234 - 250"},"PeriodicalIF":6.9,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142930473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Canine mammary tumors as a promising adjunct preclinical model for human breast cancer research: similarities, opportunities, and challenges 犬乳腺肿瘤作为人类乳腺癌研究的有前途的辅助临床前模型：相似性，机遇和挑战。

IF 6.9 3区医学

Archives of Pharmacal Research Pub Date : 2025-01-03 DOI: 10.1007/s12272-024-01524-y

Zeeshan Ahmad Bhutta, Kyung-Chul Choi

{"title":"Canine mammary tumors as a promising adjunct preclinical model for human breast cancer research: similarities, opportunities, and challenges","authors":"Zeeshan Ahmad Bhutta, Kyung-Chul Choi","doi":"10.1007/s12272-024-01524-y","DOIUrl":"10.1007/s12272-024-01524-y","url":null,"abstract":"<div><p>Despite significant progress in the field of human breast cancer research and treatment, there is a consistent increase in the incidence rate of 0.5 percent annually, posing challenges in the development of effective novel therapeutic strategies. The failure rate of drugs in clinical trials stands at approximately 95%, primarily attributed to the limitations and lack of reliability of existing preclinical models, such as mice, which do not mimic human tumor biology. This article examines the potential utility of canine mammary tumors as an adjunct preclinical model for investigating human breast cancer. Given the numerous similarities between canine and human breast cancer, canines present a promising alternative model. The discussion delves into the intricate molecular and clinical aspects of human breast cancer and canine mammary tumors, shedding light on the tumors' molecular profiles, identifying specific molecular markers, and the application of radiological imaging modalities. Furthermore, the manuscript addresses the current constraints of preclinical cancer studies, the benefits of using canines as models, and the obstacles linked to the canine mammary tumors model. By concentrating on these elements, this review aims to highlight the viability of canine models in enhancing our understanding and management of human breast cancer.</p></div>","PeriodicalId":8287,"journal":{"name":"Archives of Pharmacal Research","volume":"48 1","pages":"43 - 61"},"PeriodicalIF":6.9,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142920716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0